Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease
- Conditions
- Parkinson Disease
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT06056427
HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.
- Conditions
- Congenital Muscular Dystrophy Due to Lamin A/C Mutation
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT05154851
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndrome
Phase 2
Completed
- Conditions
- Post COVID-19 Syndrome
- Interventions
- Other: Placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 79
- Registration Number
- NCT05126563
- Locations
- 🇺🇸
Hope Biosciences Research Foundation, Sugar Land, Texas, United States
Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 24
- Registration Number
- NCT05116540
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
Phase 2
Active, not recruiting
- Conditions
- Parkinson Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 60
- Registration Number
- NCT04995081
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Target Recruit Count
- 24
- Registration Number
- NCT04928287
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
- Conditions
- System; Lupus Erythematosus
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT04907175
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
Individual Patient Expanded Access IND for the Treatment of Stroke
- Conditions
- Stroke, IschemicStroke
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT04907188
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
"Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"
- Conditions
- Primary Lateral Sclerosis, Adult, 1
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT04825613
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Hope Biosciences Stem Cell Research Foundation
- Registration Number
- NCT04825626
- Locations
- 🇺🇸
Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States